NervGen Pharma
Clinical-stage biotechnology company developing neuroreparative therapeutics to promote nervous system repair after traumatic injury and neurodegenerative disease. Activities include mechanism-focused preclinical research across multiple injury models, translational collaborations with academic partners, IND-stage regulatory engagement, and execution of early-stage clinical trials with biomarker-supported endpoints.
Industries
Nr. of Employees
small (1-50)
NervGen Pharma
112-970 Burrard Street, Unit 1290, Vancouver, BC V6Z 2R4
Products
Clinical-stage neuroreparative peptide candidate (spinal cord injury)
Clinical-stage peptide therapeutic candidate evaluated in a Phase 1b/2a proof-of-concept study for chronic and acute spinal cord injury using functional and electrophysiological endpoints.
Preclinical neuroreparative peptide candidate (ischemic stroke)
Preclinical-stage peptide therapeutic candidate evaluated in ischemic stroke and confirmatory spinal cord injury models to assess functional recovery and neural repair mechanisms.
Clinical-stage neuroreparative peptide candidate (spinal cord injury)
Clinical-stage peptide therapeutic candidate evaluated in a Phase 1b/2a proof-of-concept study for chronic and acute spinal cord injury using functional and electrophysiological endpoints.
Preclinical neuroreparative peptide candidate (ischemic stroke)
Preclinical-stage peptide therapeutic candidate evaluated in ischemic stroke and confirmatory spinal cord injury models to assess functional recovery and neural repair mechanisms.
Services
Centralized participant recruitment channels and call-center support for ongoing clinical studies.
Centralized participant recruitment channels and call-center support for ongoing clinical studies.
Expertise Areas
- Early-stage clinical trial management (Phase 1 / Phase 1b–2a)
- Mechanism-driven neuroreparative therapeutic development
- Translational research and preclinical-to-clinic translation
- Biomarker and neurophysiological outcome development
Key Technologies
- Intracellular peptide therapeutics
- Preclinical animal models (rodent and large-animal)
- Electrophysiology and neuroconnectivity assessment
- Quantitative MRI and imaging-based outcome measures
News & Updates
Company-reported expanded study data reporting durable improvements in function, independence and quality of life in individuals with chronic spinal cord injury.
Topline results from the chronic cohort reported statistical significance on a pre-specified endpoint and increased electrical connectivity between brain and spinal cord.
Reported significant functional recovery in Department of Defense-sponsored preclinical models of traumatic hearing loss and peripheral nerve injury.
Completed a non-brokered private placement to support anticipated Nasdaq listing and advance clinical development.
Announced completion of dosing of all subjects in a Phase 1 clinical trial supporting selection of doses for subsequent trials.
Company-reported expanded study data reporting durable improvements in function, independence and quality of life in individuals with chronic spinal cord injury.
Topline results from the chronic cohort reported statistical significance on a pre-specified endpoint and increased electrical connectivity between brain and spinal cord.
Reported significant functional recovery in Department of Defense-sponsored preclinical models of traumatic hearing loss and peripheral nerve injury.
Completed a non-brokered private placement to support anticipated Nasdaq listing and advance clinical development.
Announced completion of dosing of all subjects in a Phase 1 clinical trial supporting selection of doses for subsequent trials.